INTRODUCTION {#s1}
============

Cancer is one of the leading causes of mortality and is a major public health problem worldwide. It has been reported that 1,688,780 new cancer cases and 600,920 cancer deaths are projected to occur in the United States in 2017 \[[@R1]\]. Despite medical and scientific efforts over the past decades, patients with malignant tumors often face poor clinical outcomes \[[@R2]\]. It has been demonstrated that the early diagnosis and reliable prediction for recurrences are critical for the prognosis of cancer patients \[[@R3]\]. Of note, biomarkers are already important adjuvant tools for refining and optimizing diagnosis, treatment, and prognosis \[[@R4]\]. However, currently established biomarkers, due to limited validation and questionable prognostic values, could not qualify as reliable biomarkers for early diagnosis and prognosis assessment in clinical practice \[[@R5]\]. Therefore, it will be of enormous importance to identify new markers to help diagnose tumors, predict clinical outcomes and serve as therapeutic targets.

Doublecortin-like kinase 1 (DCLK1) is a microtubule-associated protein that catalyzes the polymerization of tubulin dimmers and the formation of aster-like microtubule structures \[[@R6]\]. DCLK1 has been identified to be involved in tumorigenesis of various types of cancer, such as renal cell carcinoma (RCC) \[[@R7]\], pancreatic ductal adenocarcinoma (PDAC) \[[@R8]\], colorectal cancer (CRC) \[[@R9]\] and breast carcinoma (BCA) \[[@R10]\]. In addition, it has been demonstrated that DCLK1 is associated with malignant biological behavior and poor prognosis of cancer \[[@R11], [@R12]\]. Knockdown of DCLK1 has been shown to significantly reduce invasion, migration and focal adhesion of RCC cells, indicating that DCLK1 may be a potential therapeutic target for RCC \[[@R7]\]. Although quite a number of studies have suggested that DCLK1 could be a risk factor and prognostic biomarker for malignant tumors, the relationships between expression level of DCLK1 and clinicopathological characteristics in tumors, especially for the clinical stage, lymph node metastasis and the degree of tumor differentiation, are still largely unknown and deserve further research. Therefore, we conducted the comprehensive meta-analysis on all eligible studies to clarify these and assess the clinical value of DCLK1 in cancer diagnosis and prognosis, thereby providing more evidence for clinical practice and accelerating further investigations.

RESULTS {#s2}
=======

Searching process of literature {#s2_1}
-------------------------------

The complete literature search yielded 406 articles: 116 from PubMed, 105 from Medline, 4 from Embase, 112 from Chinese National Knowledge Infrastructure (CNKI) and 69 from Wanfang databases. And 284 articles were screened based on titles and abstracts after removing 122 duplicates. Among these articles, 266 articles were excluded for the following reasons: obviously not relevant to the topic (*n =* 218), non-human studies (*n =* 18), not clearly report data of DCLK1 (*n =* 11), reviews or expert opinions (*n =* 10), contain overlapping data (*n =* 7), serum samples (*n =* 2). Finally, 18 articles were included in this meta-analysis. Figure [1](#F1){ref-type="fig"} is a flow diagram outlining the study-selection process.

![The flow diagram of study selection for meta-analysis](oncotarget-08-100545-g001){#F1}

Study characteristics {#s2_2}
---------------------

As shown in Table [1](#T1){ref-type="table"}, 18 studies \[[@R8]--[@R25]\] investigated the association between DCLK1 expression and clinicopathological characteristics in patients with cancer from 2012 to 2017, containing a total of 2660 patients with the sizes of studies distributing from 23 \[[@R18]\] to 1132 \[[@R10]\] patients. All studies were retrospective, and most of studies adopted immunohistochemistry (IHC) to detect the expression of DCLK1 in cancer tissues samples that composed of malignant cell and a supporting stroma, while one adopted reverse transcription-polymerase chain reaction (RT-PCR). The source of the malignant tumor included PDAC \[[@R8]\], CRC \[[@R9], [@R16], [@R17], [@R19], [@R22], [@R23]\], BCA \[[@R10], [@R15]\], head and neck squamous cell carcinoma (HNSCC) \[[@R11]\], non-small cell lung cancer (NSCLC) \[[@R12]\], oral squamous-cell carcinoma (OSCC) \[[@R13]\], gastric cancer (GC) \[[@R14], [@R20]\], hepatocellular carcinoma (HCC) \[[@R18]\], salivary gland carcinoma (SGC) \[[@R21]\], malignant pleural mesothelioma (MPM) \[[@R24]\] and bladder cancer (BC) \[[@R25]\]. In these studies, most of investigations were in Asia, including China and Japan. Four studies were in America \[[@R8], [@R18], [@R23], [@R24]\], and two studies were in Austria \[[@R11], [@R21]\].

###### Main characteristics of the 18 studies included in the meta-analysis

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Source   Author                           Year   Country   Enrolled period   Research\       Resources\     Test\    Cancer\    Cancer        Tumor stage\   Tumor differentiation(N)   Lymphatic Metastasis (N)                     
                                                                               design          of samples     method   /control                 (N)                                                                                    
  -------- -------------------------------- ------ --------- ----------------- --------------- -------------- -------- ---------- ------------- -------------- -------------------------- -------------------------- ----- ----- ----- -----
  CRC      Tianbo Gao \[[@R9]\]             2016   China     2007 to 2011      Retrospective   Tumor tissue   IHC      71/16      60            44/27          28                         43                         61    10    41    30

           Huan Wang \[[@R16]\]             2015   China     2007to 2012       Retrospective   Tumor tissue   IHC      150/20     58.4          91/59          \-                         \-                         95    36    66    84

           Anjun Le \[[@R19]\]              2015   China     2007 to 2008      Retrospective   Tumor tissue   IHC      70/70      52.6 ± 10.5   42/28          \-                         \-                         21    49    36    34

           Shuxiang An \[[@R17]\]           2015   China     2009 to 2013      Retrospective   Tumor tissue   IHC      60/20      \-            38/22          34                         26                         48    12    25    35

           Malaney R O'Connell \[[@R22]\]   2015   Japan     2005 to 2011      Retrospective   Tumor tissue   RT-PCR   92/0       68            57/35          49                         43                         82    10    41    51

           Giuseppe Gagliardi \[[@R23]\]    2012   USA       2000 to 2010      Retrospective   Tumor tissue   IHC      40/0       66            23/17          14                         26                         26    14    \-    \-

  GC       Lin Chen \[[@R14]\]              2015   China     2013.3 to\        Retrospective   Tumor tissue   IHC      49/49      28～70        27/22          19                         30                         22    27    36    13
                                                             2013.10                                                                                                                                                                   

           Qingbin Meng \[[@R20]\]          2013   China     2002 to 2006      Retrospective   Tumor tissue   IHC      122/122    62            86/36          \-                         \-                         \-    \-    85    37

  BCA      Jingjing Gan \[[@R15]\]          2016   China     2005 to 2007      Retrospective   Tumor tissue   IHC      129/129    53            0/129          56                         73                         86    43    94    35

           Yuhong Liu \[[@R10]\]            2015   China     2002 to 2009      Retrospective   Tumor tissue   IHC      1132/0     54.6 ± 12.7   0/1132         \-                         \-                         630   502   542   557

  NSCLC    Hiroyuki Tao \[[@R12]\]          2017   Japan     2005 to 2009      Retrospective   Tumor tissue   IHC      232/0      61            128/104        232                        \-                         \-    \-    39    193

  HCC      Sripathi M. Sureban \[[@R18]\]   2015   USA       2000 to 2010      Retrospective   Tumor tissue   IHC      23/23      62 ± 13.8     10/13          4                          18                         \-    \-    11    12

  SGC      Lorenz Kadletz \[[@R21]\]        2017   Austria   1970 to 2013      Retrospective   Tumor tissue   IHC      80/0       58            43/37          41                         39                         \-    \-    58    22

  HNSCC    Lorenz Kadletz \[[@R11]\]        2017   Austria   2002 to 2012      Retrospective   Tumor tissue   IHC      127/0      57.7          \-             20                         107                        \-    \-    99    28

  OCCC     Xin Wu \[[@R13]\]                2017   China     2013 to 2014      Retrospective   Tumor tissue   IHC      30/30      \-            \-             \-                         \-                         \-    \-    \-    \-

  PDAC     Dongfeng Qu \[[@R8]\]            2015   USA       \-                Retrospective   Tumor tissue   IHC      12/62      64            35/27          31                         31                         \-    \-    \-    \-

  MPM      Hui Wang \[[@R24]\]              2017   USA       1997 to 2008      Retrospective   Tumor tissue   IHC      73/8       68.13         \-             15                         17                         \-    \-    \-    \-

  BC       Shiqing Zhang \[[@R25]\]         2017   China     2005 to 2015      Retrospective   Tumor tissue   IHC      118/40     \-            79/39          49                         69                         80    38    16    102
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CRC, colorectal cancer; GC, gastric cancer; BCA, breast carcinoma; NSCLC, non-small cell lung cancer; HCC, hepatocellular carcinoma; SGC, salivary gland carcinoma; HNSCC, head and neck squamous cell carcinoma; OSCC, oral squamous-cell carcinoma; PDAC, pancreatic ductal adenocarcinoma; MPM, malignant pleural mesothelioma; BC, bladder cancer; IHC, immunohistochemistry, RT-PCR, real time polymerase chain reaction.

Cancer group vs. control group {#s2_3}
------------------------------

Eleven studies investigated the expression patterns of DCLK1 in various cancer and normal tissues \[[@R9], [@R13]--[@R20], [@R24], [@R25]\], which included 742 cancer cases and 508 normal controls (Table [2](#T2){ref-type="table"}). The overall odds ratio (OR) was 10.00 (95% CI = 7.20--13.89) (Z = 13.75, *p \<* 0.001) (Figure [2A](#F2){ref-type="fig"}). Subgroup analysis was stratified according to geographic region. The summary OR in Asian region was 9.25 (95% CI = 6.61--2.94, *P \<* 0.001) and 48.61 (95% CI = 5.89--401.25, *P \<* 0.001) in non-Asia region (Table [3](#T3){ref-type="table"}). Significant association existed between DCLK1 level and cancer tissues, indicating that expression of DCLK1 was dramatically higher in cancer tissues than that in normal tissues.

###### DCLK1 expression in control and cancer patients

  Author                                               Expression of DCLK1 (positive/all) (*n*)   Diagnostic test                                                                
  -------------------------------- -------- ---------- ------------------------------------------ ----------------- --------- --------- --------- --------- ---- ---- ---- ----- --------------------
  Tianbo Gao \[[@R9]\]             5/16     43/71      10/28                                      33/43             36/61     7/10      31/41     12/30     43   5    28   11    \-
  Huan Wang \[[@R16]\]             0/20     95/150     \-                                         \-                38/95     16/36     26/66     34/84     95   0    55   20    \-
  Anjun Le \[[@R19]\]              3/70     29/70      \-                                         \-                4/21      25/49     20/36     9/34      29   3    41   67    \-
  Shuxiang An \[[@R17]\]           4/20     39/60      18/34                                      21/26             23/48     6/12      20/25     19/35     39   4    21   16    \-
  Malaney R O'Connell \[[@R22]\]   \-       46/92      20/49                                      26/43             40/82     6/10      25/41     21/51     \-   \-   \-   \-    3.55 (1.41--8.99)
  Giuseppe Gagliardi \[[@R23]\]    \-       27/40      10/14                                      17/26             8/26      4/14      \-        \-        \-   \-   \-   \-    4.16 (1.28--13.57)
  Lin Chen \[[@R14]\]              18/49    36/49      7/19                                       22/30             6/22      18/27     25/36     4/13      36   18   13   31    \-
  Qingbin Meng \[[@R20]\]          4/122    51/122     \-                                         \-                \-        \-        41/85     10/37     51   4    71   118   2.27 (1. 36--3.80)
  Jingjing Gan \[[@R15]\]          15/129   58/129     18/56                                      40/73             28/86     30/43     48/94     10/35     58   15   71   114   2.12 (1.24--3.71)
  Yuhong Liu \[[@R10]\]            \-       418/1132   \-                                         \-                277/630   141/502   178/542   222/557   \-   \-   \-   \-    \-
  Hiroyuki Tao \[[@R12]\]          \-       33/232     33/232                                     \-                \-        \-        5/39      28/193    \-   \-   \-   \-    1.80 (1.13--2.85)
  Sripathi M. Sureban \[[@R18]\]   0/20     19/23      3/4                                        16/18             \-        \-        9/11      10/12     15   1    8    19    \-
  Lorenz Kadletz \[[@R21]\]        \-       53/80      9/41                                       11/39             \-        \-        15/58     6/22      \-   \-   \-   \-    \-
  Lorenz Kadletz \[[@R11]\]        \-       66/127     \-                                         \-                \-        \-        50/99     15/28     \-   \-   \-   \-    2.00 (1.20--3.40)
  Xin Wu \[[@R13]\]                4/30     23/30      \-                                         \-                \-        \-        \-        \-        23   4    7    26    \-
  Dongfeng Qu \[[@R8]\]            \-       23/44      10/22                                      13/22             \-        \-        \-        \-        \-   \-   \-   \-    \-
  Hui Wang \[[@R24]\]              0/8      37/73      9/15                                       9/17              \-        \-        \-        \-        38   35   0    8     \-
  Shiqing Zhang \[[@R25]\]         5/40     65/118     18/49                                      47/69             40/80     25/38     15/16     50/102    66   52   5    35    3.35 (2.01--5.6)

*n,* cases; TP, true positive; FP, false positive; FN, false negative; TN, true negative; OS, overall survival; HR, hazard ratio; U, univariate analysis

![Forest plot of odd ratio (OR) of subgroup analysis\
(**A**) subgroup analysis based on control tissues; (**B**) subgroup analysis based on TNM stage; (**C**) subgroup analysis based on lymphatic metastasis; (**D**) subgroup analysis based on differentiation.](oncotarget-08-100545-g002){#F2}

###### Subgroup analysis of study region

  ----------------------------------------------------------------------------------------------------------------------------------------
  Subgroup                     Region     Study (*n*)\   Patients\   Controls\   OR/HR   (95% Conf.Interval)   *Z*     *P*        I^2^
                                          number         (*n*)       (*n*)                                                        
  ---------------------------- ---------- -------------- ----------- ----------- ------- --------------------- ------- ---------- --------
                               overall    11             742         508         10.00   (7.20--13.89)         13.75   \< 0.001   44.00%

  **Cancer vs. control**       Asia       9              649         460         9.25    (6.61--12.94)         12.99   \< 0.001   39.90%

                               non-Asia   2              96          48          48.61   (5.89--401.25)        3.61    \< 0.001   13.50%

                               overall    11             380         266         2.48    (1.82--3.38)          5.78    \< 0.001   18.80%

  **TNM stage**                Asia       6              284         188         3.29    (2.28--4.76)          6.34    \< 0.001   0.00%

                               non-Asia   5              96          78          1.21    (0.67--2.19)          3.02    \< 0.001   0.00%

                               overall    14             1172        1199        2.18    (1.53--3.11)          4.31    \< 0.001   55.60%

  **Lymph node metastasis**    Asia       11             1013        1155        2.76    (2.29--3.33)          10.58   \< 0.001   46.50%

                               non-Asia   3              159         44          0.90    (0.48--1.71)          0.32    \> 0.05    0.00%

                               overall    10             389         1411        1.83    (1.45--2.31)          5.06    \< 0.001   37.80%

  **Differentiation degree**   Asia       9              375         1385        1.87    (1.47--2.37)          5.16    \< 0.001   40.80%

                               non-Asia   1              14          26          0.90    (0.22--3.75)          0.14    \> 0.05    \-

                               overall    7              860         291         2.15    (1.64--2.65)          8.33    \< 0.001   0.00%

  **OS**                       Asia       5              693         \-          2.17    (1.60--2.74)          7.44    \< 0.001   0.00%

                               non-Asia   2              167         \-          2.07    (0.98--3.15)          3.74    \< 0.001   0.00%
  ----------------------------------------------------------------------------------------------------------------------------------------

OS, overall survival; OR, odds ratio; HR, hazard ratio.

Clinical stages of cancers: advanced stage vs. early stage {#s2_4}
----------------------------------------------------------

Eleven studies \[[@R8], [@R9], [@R14], [@R15], [@R17], [@R18], [@R21]--[@R25]\] investigated the expressions of DCLK1 in different clinical stages of cancers. Patients with cancer were divided into early stage (I-II stage) and advanced stage (III--IV stage) based on the tumor-node-metastasis (TNM) classification: 266 cancer cases of early stage and 380 cases of advanced stage (Table [2](#T2){ref-type="table"}). The overall OR was 2.48 (95% CI = 1.82--3.38) (Z = 5.78, *p \<* 0.001) via a fixed model analysis (Figure [2B](#F2){ref-type="fig"}). Subgroup analysis stratified by study region showed that the summary OR was 1.21 (95% CI = 0.67--2.19, *P \<* 0.001) in non-Asia countries while was 3.29 (95% 95% CI = 2.28--4.76, *P \<* 0.001) in Asian countries with significant association (Table [3](#T3){ref-type="table"}), suggesting that expression level of DCLK1 was dramatically higher in advanced stage group than that in early stage group.

Lymph node metastasis of cancers: positive group vs. negative group {#s2_5}
-------------------------------------------------------------------

Fourteen studies \[[@R9]--[@R12], [@R14]--[@R22], [@R25]\] investigated the expressions of DCLK1 in different status of lymphatic metastasis, including 1172 cases of positive lymphatic metastasis and 1199 cases of negative lymphatic metastasis (Table [2](#T2){ref-type="table"}). The overall OR was 2.18 (95% CI = 1.53-3.11) (*Z* = 4.31, *p \<* 0.001), indicating that expression level of DCLK1 was markedly higher in positive group than that in negative group. We used a random-effect model justified by the high heterogeneity (I^2^ = 55.60%, *p* = 0.006) (Figure [2C](#F2){ref-type="fig"}). Subgroup analysis stratified by study region showed that the summary OR of Asian studies was 2.76 (95% CI = 2.29--3.33, *p \<* 0.001) with significant association. However, the statistic significance in non-Asia region disappeared (OR = 0.9, 95% CI = 0.48-1.71, *p* \> 0.05) (Table [3](#T3){ref-type="table"}).

Degree of tumor differentiation: poor group vs. well and moderate group {#s2_6}
-----------------------------------------------------------------------

As shown in Table [2](#T2){ref-type="table"}, ten studies \[[@R9], [@R10], [@R14]--[@R17], [@R19], [@R22], [@R23], [@R25]\] investigated the expressions of DCLK1 in different degree of tumor differentiation, including 1411 cases of well and moderate differentiation and 389 cases of poor differentiation. The overall OR was 1.83 (95% CI = 1.45-2.31) (Z = 5.06, *p \<* 0.001), indicating that expression level of DCLK1 was relatively higher in the poor group than that in the well and moderate group (Figure [2D](#F2){ref-type="fig"}). Subgroup analysis stratified by study region showed that the summary OR in Asian region was 1.87 (95% CI = 1.47-2.37, *p \<* 0.001) and 0.9 (95% CI = 0.22--3.75, *P* \> 0.05) in non-Asia region (Table [3](#T3){ref-type="table"}). Significant association only existed in Asia.

Correlation between DCLK1 expression and overall survival (OS) {#s2_7}
--------------------------------------------------------------

In order to investigate the association between DCLK1 expression and clinical outcome in malignant tumors, patients were divided into DCLK1-high and DCLK1-low groups. Based on the results of univariate analysis in the original studies, a total of 7 pairs of hazard ratio (HR) for OS were available in the 18 studies \[[@R11], [@R12], [@R15], [@R20], [@R22], [@R23], [@R25]\] (Table [2](#T2){ref-type="table"}). The combined HR was 2.15 (95% CI = 1.64--2.65) (Z = 8.33, *p \<* 0.001) (Figure [3](#F3){ref-type="fig"}). Subgroup analysis stratified by study region showed that the summary HR in Asian region was 2.17 (95% CI = 1.60-2.74, *p \<* 0.001) and 2.07 (95% CI = 0.98--3.15, *p \<* 0.001) in non-Asia region. Significant association existed between DCLK1 level and OS (Table [3](#T3){ref-type="table"}), indicating that DCLK1 may act as a potential marker for predicting survival outcomes in patients with cancer.

![Association between DCLK1 and overall survival for patients with cancer](oncotarget-08-100545-g003){#F3}

Accuracy of DCLK1 for diagnosing cancers {#s2_8}
----------------------------------------

A total of 11 studies reported sensitivity and specificity for distinguishing cancers and normal tissues \[[@R9], [@R13]--[@R20], [@R24], [@R25]\]. The computation of Spearman correlation coefficient between the logit of sensitivity and logit of 1-specificity showed no evidence of a threshold effect (Spearman correlation coefficient = --0.58; p = 0.34). The overall combined sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic score and relevant 95% CI were as follows: 0.58 (95% CI = 0.51-0.66) (Figure [4A](#F4){ref-type="fig"}), 0.90 (95% CI = 0.82--0.95) (Figure [4B](#F4){ref-type="fig"}), 5.9 (95% CI = 3.3--10.5) (Figure [4C](#F4){ref-type="fig"}), 0.46 (95% CI = 0.39--0.55) (Figure [4D](#F4){ref-type="fig"}) and 2.54 (95% CI = 1.90-3.18) (Figure [4E](#F4){ref-type="fig"}), respectively. Significant heterogeneity was observed for sensitivity (I^2^ = 78.68%, *p \<* 0.001), specificity (I^2^ = 84.66%, *p \<* 0.001), PLR (I^2^ = 64.50%, *p \<* 0.001), NLR (I^2^ = 72.03 %, *p \<* 0.001) and diagnostic score (I^2^ = 51.14 %, *p \<* 0.001). The mean diagnostic odds ratio (DOR) was 12.70 (95% CI = 6.68--24.15) (Figure [4F](#F4){ref-type="fig"}), indicating that DCLK1 level in cancer tissues could be helpful in the diagnosis of malignant tumors. The summary receiver operating characteristic (SROC) curve analysis was used to analyze the effectiveness of DCLK1 for diagnostic purposes, the corresponding area under the SROC curve (AUC) was 0.78 (Figure [4G](#F4){ref-type="fig"}), revealing moderate diagnostic accuracy overall.

![Diagnostic accuracy of DCLK1 in cancer\
(**A**) sensitivity of DCLK1 for the diagnosis of cancer; (**B**) specificity of DCLK1 for the diagnosis of cancer; (**C**) positive likelihood ratio (PLR) of DCLK1 for the diagnosis of cancer; (**D**) negative likelihood ratio (NLR) of DCLK1 for the diagnosis of cancer; (**E**) diagnostic score of DCLK1 for the diagnosis of cancer; (**F**) diagnostic odds ratio (DOR) of DCLK1 for the diagnosis of cancer; (**G**) the corresponding area under the SROC curve (AUC) of DCLK1 for the diagnosis of cancer.](oncotarget-08-100545-g004){#F4}

Meta-regression and subgroup analysis {#s2_9}
-------------------------------------

To explore the sources of high heterogeneity in sensitivity and specificity, we performed univariate meta-regression and subgroup analysis according to sample size, study design, detection method and geographic region. As shown in Figure [5](#F5){ref-type="fig"}, sample size may be a significant impact factor for the high heterogeneity in this meta-analysis. In studies with more than 50 subjects, the pooled sensitivity, specificity, PLR, NLR, DOR, AUC of DCLK1 were 0.62 (95% CI = 0.44--0.77), 0.85 (95% CI = 0.67--0.94), 4.1 (95% CI = 2.1--7.9), 0.45 (95% CI = 0.32--0.62), 9 (95% CI = 5--116) and 0.79, respectively. And those for studies with fewer subjects were 0.76 (95% CI = 0.67--0.84), 0.78 (95% CI = 0.68-0.86), 4.78 (95% CI = 1.21--18.88), 0.30 (95% CI = 0.20-0.47), 17 (95% CI = 3--93) and 0.81, respectively, which indicated a comparable diagnostic accuracy between the large- and small-sample studies. Similar results were found in the subgroup analyses according to study design, detection method and geographic region (Table [4](#T4){ref-type="table"}).

![Univariable meta-regression and subgroup analysis](oncotarget-08-100545-g005){#F5}

###### Summarized results of diagnostic criteria

  Subgroup           Category         Study number   Patients(n)   Controls(n)         Sensitivity         Specificity          PLR                 NLR                 DOR          AUC
  ------------------ ---------------- -------------- ------------- ------------------- ------------------- -------------------- ------------------- ------------------- ------------ ------
  **All combined**   Overall          11             674           488                 0.58 (0.51--0.66)   0.90 (0.82--0.95)    5.9 (3.3--10.5)     0.46 (0.39--0.55)   13 (7--24)   0.78
  **Sample size**    ≥ 50             8              572           389                 0.62 (0.44--0.77)   0.85 (0.67--0.94)    4.1 (2.1--7.9)      0.45 (0.32--0.62)   9 (5--116)   0.79
  \> 50              3                102            99            0.76 (0.67--0.84)   0.78 (0.68--0.86)   4.78 (1.21--18.88)   0.30 (0.20--0.47)   17 (3--93)          0.81         
  **Blinded**        Yes              6              475           361                 0.55 (0.44--0.67)   0.95 (0.87--0.98)    10.9 (3.9--30.2)    0.47 (0.36--0.62)   23 (7--76)   0.85
  No                 5                199            127           0.78 (0.52--0.92)   0.67 (0.40--0.86)   2.4(1.4--4.1)        0.33 (0.18--0.62)   7 (4--14)           0.79         
  **Method**         Multiplication   5              335           261                 0.58 (0.44--0.72)   0.90 (0.73--0.97)    6.0 (2.1--16.8)     0.46 (0.34--0.63)   13 (4--39)   0.77
  Addition           6                339            227           0.75 (0.44--0.92)   0.78 (0.54--0.92)   3.5 (1.9--6.4)       0.32 (0.14--0.72)   11 (6--22)          0.84         
  **Region**         Asia             9              614           424                 0.58 (0.49--0.65)   0.88 (0.79--0.93)    4.6 (2.9--7.5)      0.48 (0.42--0.56)   10 (6--16)   0.76
  non-Asia           2                60             64            0.93 (0.84--0.98)   0.44 (0.31--0.57)   6.06 (0.00--7848)    0.18 (0.08--0.39)   54 (5--530)         --           

PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio; AUC, corresponding area under the summary receiver operating characteristic curve.

Quality assessment of studies {#s2_10}
-----------------------------

Two reviewers evaluated the quality of each study independently, most of 18 studies had more than 5 stars of scores based on Newcastle-Ottawa Scale (NOS) ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Figure [6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"} showed the results of study methodological quality evaluation according to Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) items, suggesting that the overall quality of included studies was moderate to high.

![Assessment of methodological quality of diagnostic accuracy studies\
(**A**) risk of bias and applicability concerns summary; (**B**) risk of bias and applicability concerns graph.](oncotarget-08-100545-g006){#F6}

Publication bias and sensitivity analysis {#s2_11}
-----------------------------------------

The funnel plot was used to evaluate publication bias, and the shape of the funnel appeared to be approximately symmetrical. Furthermore, no significant publication bias was detected by Egger's test and Deeks' funnel plot ([Supplementary Figures 1 and 2](#SD1){ref-type="supplementary-material"}). The stability of the results was detected by sensitivity analysis, we found that exclusion of individual studies has no effect on the overall results ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#s3}
==========

In this meta-analysis including 18 retrospective studies with a total of 2660 patients, we clarified the association between expression of DCLK1 and the clinicopathological characteristics of malignant tumors. Our results indicated that the expression of DCLK1 in cancer tissues was significantly higher than that in normal or adjacent non-tumor tissues. After implementing a series of subgroup analysis, we noticed that high expression of DCLK1 was significantly correlated with poorly differentiated cancers, positive lymph node metastasis and advanced clinical stage, suggesting that overexpression of DCLK1 markedly accelerated the pathogenesis and development of cancer. Furthermore, we also found that patients with high DCLK1 expression had significantly poor overall survival, indicating that DCLK1 may be a promising biomarker that helps to identify patients with a high risk for recurrence in cancer. In subgroup analysis stratified by geographic region (Asia vs non-Asia), overexpression of DCLK1 was significantly correlated with advanced clinical stage and poor overall survival for all people, and non-significant heterogeneity was found (I^2^ = 0.00%). However, high DCLK1 expression was only notably correlated with positive lymph node metastasis and poorly differentiated cancer in Asian region but not in non-Asia region.

Additionally, we assessed the diagnostic accuracy of DCLK1 in malignant tumors. The overall pooled sensitivity and specificity were 0.58 (95% CI = 0.51--0.66) and 0.90 (95% CI = 0.82--0.95), respectively, which suggested that DCLK1 had a relatively considerable accuracy in detecting malignant tumors. The PLR of 5.9 (95% CI = 3.3--10.5) suggested that patients with cancer have a 5.9-fold higher chance of being DCLK1 test positive compared to individuals without cancer. Similarly, the NLR of 0.46 (95% CI = 0.39--0.55) indicated that low expression of DCLK1 might help exclude non-cancer individuals. These ratios suggested a potential role of DCLK1 for clinical confirmation and exclusion purpose. The DOR is the ratio of the odds of positivity in patients relative to the odds of positivity in control subjects, with higher values indicating better discriminatory test performance. In our meta-analysis, the value of DOR was 13, indicating that DCLK1 could be used as a biomarker for the diagnosis of malignant tumors. When sensitivity and specificity were considered simultaneously, the AUC of DCLK1 was 0.78, suggesting that the test performance of DCLK1 in discerning cancer tissues is reasonably good.

Studies have shown that DCLK1 negatively regulates tumor suppressor miRNAs and promotes epithelial-mesenchymal transition (EMT), a process through which polarized epithelial cells undergo multiple biochemical changes, leading to a mesenchymal phenotype, such as enhanced migratory capacity, invasiveness, and resistance to apoptosis \[[@R9], [@R18], [@R26]\]. Furthermore, DCLK1 has been shown to decrease tumor suppressor miRNAs let-7a, miR-200, miR-144*,* and miR-143/145 and subsequently up-regulate their downstream targets, including c-MYC, EMT-associated transcription factors ZEB1, ZEB2, Snail and Slug in HCC, CRC and PDAC, thereby promoting the development of cancer \[[@R9], [@R18], [@R27]\]. In addition, DCLK1 also regulates Notch-1 via a miR-144 dependent mechanism and its downstream effector HES1 to promote tumor xenograft growth \[[@R28]\]. Knockdown of DCLK1 or application of small molecule kinase inhibitors for DCLK1 could result in a delay of tumor development by down-regulating miRNAs downstream pluripotency transcription factors, EMT and critical oncogenic pathways \[[@R18], [@R26], [@R27], [@R29]\]. Recently, it has been reported that combination of DCLK1 inhibition with irradiation has a synergistic effect in HNSCC cell lines \[[@R11]\]. DCLK1 is therefore considered as an attractive and potential therapeutic target in the treatment of malignant tumors \[[@R30], [@R31]\]. Due to the limitations of currently available evidence on the therapeutic effects and molecular biology of DCLK1 in malignant tumors, Further studies are warranted to investigate these in more detail.

There was significant heterogeneity exiting across the included studies, which is a potential obstacle. Firstly, the heterogeneity was probably due to differences in cancer types included in this meta-analysis. Secondly, variable cut-off points were used in different studies, which may lead to the threshold effect contributing to heterogeneity, even calculated Spearman correlation coefficient value was --0.58 (*p* = 0.34). In addition, we found DCLK1 has higher diagnostic accuracy for malignant tumors in small samples using univariate meta-regression analysis and subgroup analysis, suggesting that sample size may be partially the cause of heterogeneity in sensitivity and specificity.

Though it was the first meta-analysis to assess the diagnostic and prognostic role of DCLK1 in cancer, there were still several limitations in our study. First, the majority of the studies in this meta-analysis were retrospective investigations conducted in Asia, which may result in potential selection bias. Second, despite a systematic and exhaustive literature search was performed, the sample sizes and number of included studies were relatively small, which may place restrictions on evaluating the diagnostic performance of DCLK1. Third, we could not determine the optimal cut-off value for DCLK1 due to use of different cut-off values for the examined sample set.

Despite these limitations, the meta-analysis still provided credible evidence that up-regulation of DCLK1 was an early event in the carcinogenesis and progression of malignant tumors. Expression level of DCLK1 was closely correlated to tumor differentiation, lymph node invasion and clinical phase of the patients. It was useful for predicting development of malignant tumors and clinical outcome of cancer patients. In addition, DCLK1 was potential to be a promising diagnostic and prognostic biomarker for malignant tumors, and might serve as an attractive therapeutic target in the treatment of malignant tumors.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

Two independent reviewers performed a comprehensive and systematic literature search to identify relevant studies from the databases of PubMed, Medline, Embase, Chinese National Knowledge Infrastructure (CNKI) and Wanfang databases (from inception through July 2017). The search strategy used following free text and Medical Subject Heading terms to increase sensitivity. The search strings was: ("cancer" or "tumor" or "carcinoma" or "tumors" or "neoplasm" or "malignant neoplasm" or "malignant tumors") and ("Doublecortin and CaM kinase-like-1" or "Doublecortin-like kinase 1" or "DCLK1" or "KIAA0369"). All searches were restricted to English and Chinese publications. The reference lists of relevant articles were manually searched.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

The inclusion criteria: (1) sufficient data on DCLK1 expression in malignant tumors; (2) case-control, cross-sectional, or cohort studies; (3) inclusion of pathologically confirmed patients; (4) patient tissues were taken prior to chemotherapy, radiotherapy and other drug treatment. The exclusion criteria: (1) reviews, editorials, expert opinions and case reports; (2) no useful data reported; (3) non-human studies; (4) unqualified or did not provide sufficient data.

Data extraction and quality assessment of studies {#s4_3}
-------------------------------------------------

We carried out this meta-analysis in accordance with PRISMA guidelines \[[@R32]\]. The following types of characteristics were extracted: study characteristics (the name of first author, publication year, country, enrolled period, study design and testing method of DCLK1), patient characteristics (age, sex, numbers of patients, case number of different groups, histological classification, tumor differentiation degree, tumor node metastases, TNM classification, HR and 95% CI), and concrete data of DCLK1 expression (number of true positives, false negatives, false positives, and true negatives). We systematically assessed the quality of primary studies using the Newcastle-Ottawa Scale (NOS) \[[@R33]\], and assessed the methodological quality based on the QUADAS-2 list to ensure that the enrolled studies were accurate and reliable \[[@R34]\]. Any disagreements were discussed and resolved by consensus.

Statistical analysis {#s4_4}
--------------------

After sufficient data were collected and identified, we calculated the pooled OR and 95% CI using two different meta-analysis approaches according to heterogeneity. The chi-squared test and *I*^2^ test were used to evaluate the heterogeneity of the studies and considered significant at *p \<* 0.1 or I^2^ \> 50% \[[@R35]\]. We calculated the effect sizes using fixed effects models with low heterogeneity (I^2^ \< 50% or *p* \> 0.1). Otherwise, a random-effects model was presented \[[@R36]\]. If necessary, we performed meta-regression and subgroup analysis to explore potential sources of heterogeneity. Pooled sensitivity, specificity, PLR, NLR, DOR and their 95%CI were displayed as forest plots \[[@R37]\]. In addition, we extracted the HR and 95%CI from the papers to perform meta-analysis of HR to determine the association of DCLK1 expression with survival of patients. Funnel plots, Egger's test and Deeks' funnel plot were implemented to measure potential publication bias, *p* ≥ 0.05 indicates no publication bias \[[@R38], [@R39]\], and sensitivity analysis was performed to evaluate whether exclusion of any individual study affects the overall results. All statistical analyses were performed using STATA software (Version 12.0; STATA Corporation, College Station, TX). Two-tailed *p* values \< 0.05 were considered statistically significant (except for the heterogeneity and publication bias tests already mentioned).
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CRC

:   colorectal cancer

GC

:   gastric cancer

BCA

:   breast carcinoma

NSCLC

:   non-small cell lung cancer

HCC

:   hepatocellular carcinoma

SGC

:   salivary gland carcinoma

HNSCC

:   head and neck squamous cell carcinoma

OSCC

:   oral squamous-cell carcinoma

PDAC

:   pancreatic ductal adenocarcinoma

MPM

:   malignant pleural mesothelioma

BC

:   bladder cancer

IHC

:   Immunohistochemistry

RT-PCR

:   real time polymerase chain reaction

TP

:   true positive

FP

:   false positive

FN

:   false negative

TN

:   true negative

OS

:   overall survival

HR

:   hazard ratio

U

:   univariate analysis

DCLK1

:   Doublecortin-like kinase 1

OR

:   odds ratio

PLR

:   positive likelihood ratio

NLR

:   negative likelihood ratio

DOR

:   diagnostic odds ratio

SROC

:   summary receiver operating characteristic
